S-23 Weight Loss Sarms Steroids Powder Fat Burning Cutting Cycle High Purity
What is S-23?
Full Name: (2S)-N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide
S-23 is an investigational selective androgen receptor modulator (SARM), Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment.
Anabolic steroids and prohormones are the “in” thing for many athletes and bodybuilders. But, with the entry of SARMS a.k.a. Selective Androgen Receptor Modulators in the supplement industry, many have made the big switch. SARMS offer the same benefits of traditional anabolic androgen steroids such as increase in testosterone, lean muscle mass, fat loss and bone density, while offering a lower risk of producing the negative side effects that come with steroids.
What is S23?
S23 or (2S)-N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide is a new SARM from GTX, Inc. which is developed as a possible male hormonal contraceptive. It links to the androgen receptor (AR) more intensely (with a Ki of 1.7nM) as compared to older medicines such as Andarine.
In animal research, S23 displayed a good ratio of anabolic to androgenic effects as well as dose-dependent restraint of spermatogenesis (the course of sperm cell development) with unprompted recuperation after end of treatment.
Chemical Formula: C18H13ClF4N2O3
||acts by entering nucleoside pools, significantly increasing levels of adenosine
during periods of ATP breakdown
||medical prescription for prevention of cachexia, atrophy, and sarcopenia and
for Hormone or Testoserone Replacement Therapy.
for the treatment of frailty in the elderly
||pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
||For obesity, diabetes, dyslipidemia and cardiovascular disease
||partial agonist, intended mainly for treatment of benign prostatic hypertrophy
||under development at The Scripps Research Institute (TSRI),
increases the level of metabolic activity in skeletal muscles of mice
||New generation for gaining mass and cutting edges
||YK11: a SARM and myostatin inhibitor in one
S-23 Weight Loss Sarms Steroids Powder Fat Burning Cutting Cycle High Purity Images